Earlier this month, the New York State Department of Health announced new emergency regulations to allow patients prescribed opioids to be given a license to obtain medicinal cannabis as an alternative.
Opioids are synthetic based medicines that product effects similar to morphine. They are primarily used for pain management and are prescribed often by practitioners. Unfortunately the use of them has caused a wide spread epidemic. 91 Americans die everyday from opioid overdoses, more than car accidents and guns.
Medicinal cannabis has recently been found to be an all natural alternative to using opioids for the management of pain. Cannabis can also reduce the chance for dependence and as opposed to opioids, patients cannot overdose when consuming the plant. Most patients have reported that it is just as affection as using opioids.
Patients that qualify for this program will be given temporary registry ID cards that will allow them to purchase their medical cannabis.
“Medical marijuana has been shown to be an effective treatment for pain that may also reduce the chance of opioid dependence,” said New York State Health Commissioner Dr. Howard Zucker. “Adding opioid replacement as a qualifying condition for medical marijuana offers providers another treatment option, which is a critical step in combatting the deadly opioid epidemic affecting people across the state.”
Opioid replacement joins the following 12 qualifying conditions under the state’s Medical Marijuana Program: cancer; HIV infection or AIDS; amyotrophic lateral sclerosis (ALS); Parkinson’s disease; multiple sclerosis; spinal cord injury with spasticity; epilepsy; inflammatory bowel disease; neuropathy; Huntington’s disease; post-traumatic stress disorder; and chronic pain.
You may be interested
Columbia Care Receives Licenses from Maltese GovernmentEditor - November 15, 2018
Columbia Care LLC. has announced this morning that the company has gain approval from Malta Enterprises, the regulatory economic development agency in the country, to receive licenses…
Tilray Announces Impressive 2018 Q3 FinancialsEditor - November 14, 2018
Wholly-owned subsidiary of Privateer Holdings, Inc., Tilray (NASDAQ: TLRY), has announced the company’s third quarter financial statements for 2018 this morning. Earlier this year, Tilray debuted its…
Valens Signs Cannabidnoid Extraction and R&D Agreement with Harvest OneEditor - November 14, 2018
Valen GroWorks Corp. (CSE: VGW) (OTC-QB: MYMSF) has announced this morning that the company has entered into an agreement with Harvest One (TSXV:HVT) to provide services in…